Suppr超能文献

肺血管阻力可预测移植患者合并门脉高压肺血管病患者的死亡率和移植物失功。

Pulmonary Vascular Resistance Predicts Mortality and Graft Failure in Transplantation Patients With Portopulmonary Hypertension.

机构信息

Division of Pulmonary, Critical Care, and Sleep MedicineUniversity of CincinnatiCincinnatiOH.

Department of SurgeryUniversity of CincinnatiCincinnatiOH.

出版信息

Liver Transpl. 2021 Dec;27(12):1811-1823. doi: 10.1002/lt.26091. Epub 2021 Jun 29.

Abstract

Portopulmonary hypertension (POPH) is a pulmonary vascular disease associated with significant morbidity and mortality in those with liver disease, conferring a higher mortality in patients awaiting liver transplantation (LT). Although not a transplant indication, patients with POPH can experience significant clinical improvement following LT, and those maintaining a mean pulmonary artery pressure (MPAP) <35mm Hg and a pulmonary vascular resistance (PVR) <5 Woods units (WU) are granted additional listing points to expedite LT. The effect of POPH on posttransplant outcomes such as mortality and graft failure, however, is not well defined. We performed a retrospective cohort study of the US Organ Procurement and Transplantation Network database of all adult patients who underwent LT between January 1, 2006, and December 1, 2020. Using adjusted accelerated failure time models, we examined the relationship between a diagnosis of POPH and outcomes following LT and the relationship between pre-LT hemodynamics and post-LT survival (alive with a functioning graft) in patients with POPH. Compared with those undergoing transplants without exception points, patients with POPH had comparable post-LT survival rates but were significantly more likely to have graft failure. Both pre-LT MPAP and PVR predicted post-LT survival in POPH, with a pre-LT PVR of ≥1.6 WU, more than doubling the hazard for mortality (death or a nonfunctioning graft; coefficient, 2.01; standard error, 0.85; hazard ratio, 2.21; P = 0.02). POPH may confer a significantly higher risk of post-LT graft failure compared with patients with cirrhosis without POPH, and a pre-LT PVR of ≥1.6 WU may predict post-LT survival. Further investigation into the relationship between pre-LT hemodynamics, right ventricular function, and post-LT outcomes of mortality and graft failure in POPH is needed.

摘要

肝肺高压(POPH)是一种与肝病患者显著发病率和死亡率相关的肺血管疾病,在等待肝移植(LT)的患者中死亡率更高。尽管 POPH 不是移植的适应证,但在 LT 后,患者可以经历显著的临床改善,并且那些平均肺动脉压(MPAP)<35mmHg 和肺血管阻力(PVR)<5 伍德单位(WU)的患者可以获得额外的移植点,以加快 LT 的进程。然而,POPH 对移植后结局(如死亡率和移植物衰竭)的影响尚未明确。我们对 2006 年 1 月 1 日至 2020 年 12 月 1 日期间接受 LT 的美国器官采购和移植网络数据库中的所有成年患者进行了回顾性队列研究。使用调整后的加速失效时间模型,我们检查了 POPH 诊断与 LT 后结局之间的关系,以及 POPH 患者 LT 前血液动力学与 LT 后存活(带功能移植物存活)之间的关系。与没有例外点的移植患者相比,POPH 患者的 LT 后生存率相当,但移植物衰竭的风险明显更高。LT 前的 MPAP 和 PVR 均预测了 POPH 患者的 LT 后生存率,LT 前的 PVR≥1.6WU,使死亡率(死亡或无功能移植物)的危险增加一倍以上(系数,2.01;标准误差,0.85;危险比,2.21;P=0.02)。与没有 POPH 的肝硬化患者相比,POPH 可能会导致 LT 后移植物衰竭的风险显著增加,而 LT 前的 PVR≥1.6WU 可能预测 LT 后生存率。需要进一步研究 POPH 中 LT 前血液动力学、右心室功能与 LT 后死亡率和移植物衰竭结局之间的关系。

相似文献

3
Predictors of Waitlist Mortality in Portopulmonary Hypertension.
Transplantation. 2017 Jul;101(7):1609-1615. doi: 10.1097/TP.0000000000001666.
4
Clinical Outcomes After Liver Transplantation in Patients With Portopulmonary Hypertension.
Transplantation. 2021 Oct 1;105(10):2283-2290. doi: 10.1097/TP.0000000000003490.
5
Sex Differences in Portopulmonary Hypertension.
Chest. 2021 Jan;159(1):328-336. doi: 10.1016/j.chest.2020.07.081. Epub 2020 Aug 13.
7
Portopulmonary hypertension: an update.
Liver Transpl. 2012 Aug;18(8):881-91. doi: 10.1002/lt.23485.
8
Outcomes of liver transplantation for porto-pulmonary hypertension in model for end-stage liver disease era.
Dig Dis Sci. 2014 Aug;59(8):1976-82. doi: 10.1007/s10620-014-3065-y. Epub 2014 Feb 21.
9
Outcomes of Liver Transplantation in Treated Portopulmonary Hypertension Patients With a Mean Pulmonary Arterial Pressure ≥35 mm Hg.
Transplant Direct. 2020 Nov 10;6(12):e630. doi: 10.1097/TXD.0000000000001085. eCollection 2020 Dec.
10
Association of Cardiopulmonary Hemodynamics and Mortality in Veterans With Liver Cirrhosis: A Retrospective Cohort Study.
J Am Heart Assoc. 2024 Apr 16;13(8):e033847. doi: 10.1161/JAHA.123.033847. Epub 2024 Apr 3.

引用本文的文献

1
Rare but serious: pulmonary vascular disease around the world.
JHLT Open. 2025 Jul 18;9:100327. doi: 10.1016/j.jhlto.2025.100327. eCollection 2025 Aug.
2
Portopulmonary hypertension: Current developments and future perspectives.
Liver Res. 2022 Mar 3;6(1):10-20. doi: 10.1016/j.livres.2022.02.002. eCollection 2022 Mar.
4
Making Living-donor Liver Transplantation a Viable Option for Patients With Portopulmonary Hypertension.
Transplant Direct. 2024 Sep 25;10(10):e1710. doi: 10.1097/TXD.0000000000001710. eCollection 2024 Oct.
5
Association of Cardiopulmonary Hemodynamics and Mortality in Veterans With Liver Cirrhosis: A Retrospective Cohort Study.
J Am Heart Assoc. 2024 Apr 16;13(8):e033847. doi: 10.1161/JAHA.123.033847. Epub 2024 Apr 3.
7
Current clinical understanding and effectiveness of portopulmonary hypertension treatment.
Front Med (Lausanne). 2023 Apr 4;10:1142836. doi: 10.3389/fmed.2023.1142836. eCollection 2023.
9
The Different Effects of Direct Bilirubin on Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension.
Int J Clin Pract. 2022 Feb 3;2022:7021178. doi: 10.1155/2022/7021178. eCollection 2022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验